Ruconest market forecast points to faster growth through 2035

The Business Research Company says the Ruconest market is set to expand through 2035 as hereditary angioedema diagnosis rises, home infusion grows and rare-disease investment increases. North America led in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Why it matters: - Ruconest targets acute hereditary angioedema attacks, a rare condition that can cause severe swelling in the face, limbs and airway. - Growth in diagnosis and treatment access could expand demand for recombinant C1 esterase inhibitors. - The forecast points to a larger market opportunity as healthcare systems invest more in rare-disease care and home-based treatment.

What happened: - The Business Research Company released its Ruconest Market Forecast Global Market Report 2026 covering market size, trends and projections for 2026-2035. - The report says the Ruconest market is evolving rapidly, driven by treatment advances and greater awareness of hereditary angioedema. - The company also posted a free sample report and the full market report.

The details: - Ruconest is a recombinant human C1 esterase inhibitor designed to treat acute hereditary angioedema attacks. - The drug supplements deficient or malfunctioning C1 inhibitor protein and is given intravenously. - The report says historical growth was supported by limited treatment alternatives, approval of recombinant C1 inhibitors, rising awareness, clinical effectiveness and adoption by specialist physicians. - The forecast period is expected to benefit from increased diagnosis of rare diseases, broader home infusion programs, more orphan-drug investment, patient-access initiatives and next-generation HAE therapies. - Expected trends include greater use of recombinant C1 esterase inhibitors, more emphasis on acute attack management, more intravenous on-demand treatment, expansion of home administration and better detection of rare angioedema disorders. - The increasing prevalence of hereditary angioedema worldwide is a major demand driver. - In August 2025, the Hereditary Angioedema Association said nearly 10,000 people in the U.S. had been diagnosed with HAE. - Personalized medicine is also supporting demand as treatments become more tailored to individual patients. - The Personal Medicine Coalition said FDA approvals for personalized treatments rose from 34% in 2022 to 38% in 2023. - Rising healthcare spending is supporting access to innovative treatments and rare-disease therapies. - The Canadian Institute for Health Information estimated Canada’s total health expenditure would reach $344 billion in 2023, up 2.8% from the prior year. - In 2025, North America was the largest Ruconest market. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report is framing Ruconest less as a standalone drug story and more as part of a broader shift toward earlier diagnosis, home treatment and precision medicine in rare disease. - The focus on recombinant C1 esterase inhibitors suggests competition and category growth may matter as much as one product’s performance. - The regional split points to mature demand in North America and faster expansion potential in markets where rare-disease awareness and access are still improving.

What's next: - The Business Research Company says future growth will depend on diagnosis rates, treatment access, and the rollout of next-generation HAE therapies. - The company added new report features for 2026, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspots infographics and updated graphics and tables.